By Topic

Nanotube Devices for Digital Profiling: A focus on cancer biomarkers and circulating tumor cells.

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$33 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

6 Author(s)
Farhad Khosravi ; Dept. of Mech. Eng., Univ. of Louisville, Louisville, KY, USA ; Benjamin King ; Sesh Rai ; Goetz Kloecker
more authors

Circulating tumor cells (CTCs) were first discovered in 1869 in the blood of patients suffering from metastatic disease by an Australian physician, Thomas Ashworth, using optical microscopy [1]. The current understanding is that these CTCs mediate the spread of cancer at distant sites, including the lungs, liver, bones, and brain. CTCs are shed by primary and metastatic cancers in the range of 1-77,200/ml [2], [3]. Recent clinically approved techniques for CTC detection include Veridex from Cell Search [4], the CTC chip [5], and the ADNA test [6], [7], to name a few. Table 1 presents a list of CTC detection methodologies and their U.S. Food and Drug Administration (FDA) approval stages. Although these methods are impressive, none are handheld point-of-care devices; the test cannot be administered in the clinic, with results available in a few minutes both for CTCs and cancer biomarkers. Therefore, with this objective in mind, we present our results on the development of nanotube devices for detection of both protein biomarkers and CTCs using nanotube devices.

Published in:

IEEE Nanotechnology Magazine  (Volume:7 ,  Issue: 4 )